The state of the art in biopharmaceutical FUSION PROTEIN DESIGN

Fusion proteins belong to the most lucrative biotech drugs--with Enbrel(R) being one of the best-selling biologics worldwide. Enbrel(R) represents a milestone of modern therapies just as Humulin(R), the first therapeutic recombinant protein for human use, approved by the FDA in 1982 and Orthoclone(R) the first monoclonal antibody reaching the market in 1986. These first generation molecules were soon followed by a plethora of recombinant copies of natural human proteins, and in 1998, the first de novo designed...